These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26545404)

  • 1. Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype.
    Sun X; Nichols HB; Tse CK; Bell MB; Robinson WR; Sherman ME; Olshan AF; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):60-7. PubMed ID: 26545404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea.
    Lee JS; Oh M; ;
    Clin Breast Cancer; 2014 Dec; 14(6):426-34. PubMed ID: 25034438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study.
    Song N; Choi JY; Sung H; Chung S; Song M; Park SK; Han W; Lee JW; Kim MK; Yoo KY; Ahn SH; Noh DY; Kang D
    Int J Cancer; 2014 Aug; 135(3):669-81. PubMed ID: 24916400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
    Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
    Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor subtype-specific associations of hormone-related reproductive factors on breast cancer survival.
    Song N; Choi JY; Sung H; Jeon S; Chung S; Song M; Park SK; Han W; Lee JW; Kim MK; Yoo KY; Ahn SH; Noh DY; Kang D
    PLoS One; 2015; 10(4):e0123994. PubMed ID: 25875532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.
    Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Stefanick ML; Vitolins M; Kabat GC; Rohan TE; Li CI
    J Natl Cancer Inst; 2011 Mar; 103(6):470-7. PubMed ID: 21346227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer subtype and survival by parity and time since last birth.
    De Mulder H; Laenen A; Wildiers H; Punie K; Poppe A; Remmerie C; Lefrère H; Nevelsteen I; Smeets A; Van Nieuwenhuysen E; Han S; Van Limbergen E; Floris G; Vergote I; Neven P
    Breast Cancer Res Treat; 2018 Jun; 169(3):481-487. PubMed ID: 29426984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproductive history and breast cancer survival: a prospective patient cohort study in Japan.
    Minami Y; Nishino Y; Kawai M; Tada H; Kanemura S; Miyashita M; Ishida T; Kakugawa Y
    Breast Cancer; 2019 Nov; 26(6):687-702. PubMed ID: 30993643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.
    Morikawa A; Jordan L; Rozner R; Patil S; Boire A; Pentsova E; Seidman AD
    Clin Breast Cancer; 2017 Feb; 17(1):23-28. PubMed ID: 27569275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.
    Lambertini M; Santoro L; Del Mastro L; Nguyen B; Livraghi L; Ugolini D; Peccatori FA; Azim HA
    Cancer Treat Rev; 2016 Sep; 49():65-76. PubMed ID: 27529149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009-2016: a cross-sectional study.
    Chitkara A; Mesa-Eguiagaray I; Wild SH; Hall PS; Cameron DA; Sims AH; Figueroa JD
    Breast Cancer Res Treat; 2022 Nov; 196(2):379-387. PubMed ID: 36116093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
    Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
    J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproductive and hormonal factors, family history, and breast cancer according to the hormonal receptor status.
    Rosato V; Bosetti C; Negri E; Talamini R; Dal Maso L; Malvezzi M; Falcini F; Montella M; La Vecchia C
    Eur J Cancer Prev; 2014 Sep; 23(5):412-7. PubMed ID: 23817433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
    Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
    Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer.
    Cespedes Feliciano EM; Kwan ML; Kushi LH; Chen WY; Weltzien EK; Castillo AL; Sweeney C; Bernard PS; Caan BJ
    Cancer; 2017 Jul; 123(13):2535-2542. PubMed ID: 28295245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.